The Competitive Intelligence Report Enzyme Replacement & Enhancement Therapies (ERT) as of February 2011 provides a competitor analysis in the development pipeline of novel enzyme replacement therapies and of enzyme enhancement therapies to treat human genetic diseases/lysosomal storage diseases and exocrine pancreatic insufficiency due to cystic fibrosis, pancreatitis and other causes.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of current active projects in research and development of novel enzyme replacement & enhancement therapy products and an overview of approved products. In addition, the report lists company-specific product portfolios and R&D pipelines of enzyme replacement and enhancement therapies. Competitor projects are listed in a tabular format providing Information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

Index
- Gaucher Disease
- Fabry Disease
- Pompé Disease
- Hunter Disease (MPS II)
- Niemann Pick Diseases
- Mucopolysaccharidosis I (MPS I)
- San Filippo Syndrome (MPS IIIA)
- Morquio Syndrome (MPS IVA)
- Mucopolysaccharidosis VI (MPS VI)
- Tay-Sachs Disease
- Krabbe Disease (Globoid Cell Leukcodystrophy)
- Metachromatic Leukodystrophy (MLD)
- Phenylketonuria / Hyperphenylalaninemia
- Other Enzyme Replacement Therapies
- Exocrine Pancreatic Insufficiency: Porcine-Derived ERT
- Exocrine Pancreatic Insufficiency: Recombinant ERT
- Others

Pharmaceutical Market Research

Enzyme Replacement Therapies

Enzyme Replacement Therapies

Contents

Related products